Scarica l'app Stockscreener
7.43
0.27%
0.010
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ATRA Giù?
Forum
Previsione
Precedente Chiudi:
$7.42
Aprire:
$7.44
Volume 24 ore:
18,728
Relative Volume:
0.31
Capitalizzazione di mercato:
$45.07M
Reddito:
$100.44M
Utile/perdita netta:
$-133.16M
Rapporto P/E:
-0.2884
EPS:
-25.76
Flusso di cassa netto:
$-94.85M
1 W Prestazione:
-4.86%
1M Prestazione:
+26.32%
6M Prestazione:
-34.22%
1 anno Prestazione:
-45.47%
Intervallo 1D:
$7.2927
$7.80
Intervallo di 1 settimana:
$6.90
$8.65
Portata 52W:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Nome
Atara Biotherapeutics Inc
Settore
Industria
Telefono
805-623-4211
Indirizzo
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Confronta ATRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
7.41 | 45.07M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.62 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
535.63 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.54 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.74 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
232.22 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-09 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-20 | Downgrade | Citigroup | Neutral → Sell |
| 2022-07-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Downgrade | Stifel | Buy → Hold |
| 2022-05-10 | Downgrade | Citigroup | Buy → Neutral |
| 2021-05-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-30 | Iniziato | Evercore ISI | Outperform |
| 2020-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-23 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Downgrade | Goldman | Neutral → Sell |
| 2019-09-16 | Downgrade | Jefferies | Buy → Hold |
| 2019-06-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2019-05-30 | Iniziato | ROTH Capital | Buy |
| 2019-05-23 | Iniziato | Stifel | Buy |
| 2019-01-23 | Iniziato | Mizuho | Buy |
| 2018-04-10 | Iniziato | JP Morgan | Overweight |
| 2018-03-16 | Iniziato | Guggenheim | Neutral |
| 2018-03-05 | Reiterato | Jefferies | Buy |
| 2018-02-28 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Downgrade | Citigroup | Neutral → Sell |
| 2018-01-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie
FDA lifts clinical hold on Atara’s Ebvallo - The Pharma Letter
FDA Lifts Hold on Atara’s EBVALLO Program - TipRanks
Atara Does An About Face As FDA Lifts Ebvallo Hold - insights.citeline.com
(ATRA) Investment Analysis - news.stocktradersdaily.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Fly 30% But Investors Aren't Buying For Growth - simplywall.st
FDA Lifts Hold on Atara Biotherapeutics' Ebvallo Program | ATRA Stock News - GuruFocus
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel) | ATRA Stock News - GuruFocus
Atara Biotherapeutics Says FDA Lifts Clinical Hold Enabling Resumption Of Clinical Trials - marketscreener.com
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel) - Business Wire
Atara Biotherapeutics, Inc. Provides Regulatory Updates on EBVALLO?? (Tabelecleucel) - marketscreener.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Acquired by Geode Capital Management LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Head-To-Head Contrast: Atara Biotherapeutics (NASDAQ:ATRA) and Creative Medical Technology (NASDAQ:CELZ) - Defense World
(ATRA) On The My Stocks Page - news.stocktradersdaily.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Trial misses sink cancer stocks in Q1: Mersana, Cargo, Mural fall - BioWorld MedTech
Layoff Tracker: Spark Lays Off 298 Employees - BioSpace
Atara Biotherapeutics stock hits 52-week low at $5.3 - Investing.com
Atara Biotherapeutics stock hits 52-week low at $5.3 By Investing.com - Investing.com UK
How the (ATRA) price action is used to our Advantage - news.stocktradersdaily.com
Atara Biotherapeutics IncOn March 31, Entered Amendment To Commercialization Agreement With Pierre FabreSEC Filing - marketscreener.com
Epstein-Barr Virus (EBV) Market Growth 2025: Trends, Consumer - openPR.com
Atara Biotherapeutics Faces Potential Liquidation: Strategic Decisions Crucial for Investor Outcomes - MSN
Long Term Trading Analysis for (ATRA) - news.stocktradersdaily.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Atara Biotherapeutics (NASDAQ:ATRA) Stock Crosses Below 50 Day Moving Average – Should You Sell? - Defense World
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, Prevalence, Therapies and Companies by DelveInsight - The Globe and Mail
(ATRA) Investment Report - news.stocktradersdaily.com
Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Atara Biotherapeutics (NASDAQ:ATRA) Given Buy Rating at Canaccord Genuity Group - Defense World
Atara Biotherapeutics: Strategic Focus on Ebvallo BLA Resubmission and Market Position Enhancement - TipRanks
SNOA's Wound Care Products Get Regulatory Clearance, LFMD's Q4 Revenue Soars, ATRA On Watch - RTTNews
Atara Biotherapeutics: Q4 Earnings Snapshot - The Bakersfield Californian
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Atara Biotherapeutics Reports 2024 Financial Results - TipRanks
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress - BioSpace
Atara Biotherapeutics Inc. (ATRA) reports earnings - Quartz
Atara Biotherapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop - Simply Wall St
Atara Biotherapeutics Inc Azioni (ATRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Atara Biotherapeutics Inc Azioni (ATRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hyllengren Eric J | EVP, CFO and COO |
Mar 03 '25 |
Sale |
7.00 |
1,211 |
8,473 |
56,231 |
| Henrich Jill | EVP, Chief Regulatory Officer |
Mar 03 '25 |
Sale |
7.00 |
1,059 |
7,410 |
18,679 |
2.11%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):